For decades, large companies have gone shopping in Silicon Valley for startups. Lately, the pressure of continuous disruption has forced them to step up the pace.
More often than not, the results of these acquisitions are disappointing.
What can companies learn from others’ failed efforts to integrate startups into large companies? The answer: There are two types of integration strategies, and they depend on where the startup is in its lifecycle.
When Bryan Sivak joined then D.C. mayor Adrian Fenty’s administration as chief technology officer, he was fresh from building his own business. Five years later, Sivak has become something of a government-embedded entrepreneur. He left the District to become Maryland’s first chief innovation officer in 2011. He is now chief technology officer at the Department of Health and Human Services. There, he manages the IDEA Lab, a series of programs that reward innovation, bring private sector leaders into the agency, and provide employees with time and money to pursue ideas. The effort aims to infuse a sense of entrepreneurship in the risk-adverse temperament of government.
Heart disease is the #1 killer of humans — claiming more lives than car accidents, war, famine, and natural disasters.
So it’ll come as good news that scientists at Johns Hopkins have found a drug that acts by stopping any hardening of the arteries, and prevents fat from clogging up blood vessels.
On an industrial park next to Liverpool’s John Lennon airport, drugs companies are involved in research that is driving a new frenzy of multibillion-dollar takeover deals. The focus on this Merseyside site is on creating what could be the next big thing for the sector: biological medicines, derived from living organisms.
In laboratories here and around the world, the quest for the latest blockbuster drug has sparked another flurry of deal activity. Last week saw GlaxoSmithKline of the UK and Swiss rival Novartis agree a multibillion dollar swap of assets, while it emerged that another British firm, AstraZeneca, has been the subject of a £60bn approach from US group Pfizer. And every participant is seeking a deal that will yield a clutch of medical bestsellers.
The EY Entrepreneur Of The Year 2014 finalists have a lot to celebrate. They’ve built their dream companies. Expanded. Innovated. And now EY is recognizing them for their achievements. Help us congratulate these outstanding entrepreneurs. Join us at this years event and see who will take home top honors.
With a pinch of history, a dash of pride, and a heaping helping of collaboration, University of Maryland, Baltimore (UMB) President Jay A. Perman, MD, put forth a winning recipe in his first annual State of the University Address.
Speaking at a packed School of Nursing auditorium on April 24 that included dignitaries such as University System of Maryland (USM) Chancellor William E. Kirwan, PhD, Perman discussed UMB’s recent achievements and the challenges it will confront in the coming year.
QIAGEN N.V. QGEN has posted its 2013 Annual Report on its website at http://www.qiagen.com/About-Us/Investors/Financial-Information/Financial-Reports .
QIAGEN’s Annual Report on Form 20-F for the year ended December 31, 2013 has been filed with the U.S. Securities and Exchange Commission (SEC) on March 04, 2014, a copy of which can be found on the website of the SEC at www.sec.gov or in the “Financial Information” section of the “Investors” section of our website at http://www.qiagen.com/About-Us/Investors/ . QIAGEN will provide printed copies of the 2013 Annual Report to shareholders free of charge upon request. To obtain a printed copy of the 2013 Annual Report please contact: IR@qiagen.com.
The potential for crowdfunding, as defined in the JOBS Act, to fundamentally change the nature of capital formation is tremendous, potentially opening up avenues to investment and borrowing that were previously only available to a small segment of the investing community, let along the general public. And one sector that could see truly revolutionary change is health care.
Maryland’s strength in the technology sector is making it one of the fastest-growing exporters of high-tech goods and services in the U.S.
Maryland ranks eighth on the list of the nation’s fastest-growing exporter of high tech goods, according to a recent report from Technology CEO Council, a public policy advocacy organization in Washington, D.C. More than 9.5 percent — or $24.425 billion — of the state’s GDP can be attributed to the tech sector.
Here I am presenting opportunities to those engaged in research for electric and other advanced vehicles, to engage in research related to their own research, earning some money for their efforts, as well as helping their country. Note: Some of these are restricted to American citizens, or certain “Permanent Resident” or “protected” foreigners. Others require watchful tracking of what the foreigners do.
The current DoD Small-Business Innovative Research (SBIR) Solicitation, 2014.2, will be open until June 25. There is a large selection of topics available. I will be selecting and rating many of these, to make it easier for readers to select topics of interest. This may take a week or so, because I first must visit the NY Auto Show and write a blog about it.
